



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,

ON December 6, 2002

*Nora Lein Fernandez*  
ATTORNEY FOR APPLICANT

*December 6, 2002*  
DATE

Attorney Docket No.: P50869

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Murphy et al.	December 6, 2002
Serial No.:	09/889,904	Group Art Unit: 1614
Filed:	January 25, 2000	Examiner: C. Delacroix-Muirheid
For:	ANTI-ANDROGENS AND METHODS FOR TREATING DISEASE	

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO COMMUNICATION FROM EXAMINER**

Dear Sir:

This Response is made to the Examiner's Communication mailed August 27, 2002. A request for a three-month extension of time accompanies this Response. Claims 9-16 are pending in this application. Reconsideration and withdrawal of the assertion that the Amendment filed June 4, 2002, was unresponsive, are respectfully requested in view of the following remarks.

Original claims 1-8 were canceled and replaced with new claims 9-16. In the Official Action mailed December 20, 2001, the Examiner rejected claims 1-4 and 6 for various reasons under 35 U.S.C. §§ 112, second paragraph, 102(b) and 102(e). Further, the Examiner stated on page 8 of the Official Action, that claims 5, 7 and 8 would be allowable if rewritten in independent form. In replacing original claims 1-8 with claims 9-16, Applicants did just that. A careful reading of claims 9-16 shows that they are modeled from original claims 5, 7 and 8 by being directed to a method for treating various diseases characterized by androgenic dependency, a method for suppressing testosterone production, and a method for suppressing the production of lutinizing hormone, with the administration of a neurokinin-3

TECH CENTER 1600/2900

DEC 20 2002

RECEIVED

1614  
1-21-03  
Ver 3

receptor antagonist. Since no rejections were made of these claims, Applicants did not address the rejections of the canceled claims. The newly presented claims are free of the art cited as they were deemed allowable if rewritten in independent format. Therefore, Applicants considered the June 4, 2002, Amendment completely responsive.

In view of the foregoing, favorable consideration of new claims 9-16 and allowance of this application are earnestly solicited.

Respectfully submitted,

*Nora Stein-Fernandez*  
Nora Stein-Fernandez  
Attorney for Applicants  
Registration No. 36,689

GLAXOSMITHKLINE  
Corporate Intellectual Property-UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone: (610) 270-5044  
Facsimile: (610) 270-5090  
n:\nsf\patapps\P50869\Amendment May 2002.doc